AK and miltefosine

May 9, 2017

 

Three weeks after treatment with oral miltefosine offers promising hope for patients with AK.  Miltefosine is not yet approved for AK but has received orphan drug designation.

Please reload

Featured Posts

CDC Video showing N.Fowleri

July 21, 2017

1/4
Please reload

Recent Posts

October 6, 2017

Please reload

Archive
Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

 Impavido® (miltefosine) is an FDA-approved treatment for cutaneous,  mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO